Repligen Corp (RGEN)

$147.06 +6.05 (4.29%)
Market Cap 7.96B
Revenue (ttm) 738.26M
Net Income (ttm) 48.89M
EPS (ttm) N/A
PE Ratio 72.89
Forward PE 69.67
Profit Margin 6.62%
Debt to Equity Ratio 0.00
Volume 1,010,500
Avg Vol 1,138,272
Day's Range N/A - N/A
Shares Out 56.44M
Stochastic %K 71%
Beta 1.06
Analysts Strong Sell
Price Target $180.70

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sampl...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 781 250 0111
Fax: 781 250 0115
Address:
Building 1, Suite 100 41 Seyon Street, Waltham, United States
vjtweet
vjtweet Aug. 4 at 2:22 AM
$RGEN Noisy but 200 should be possible in few months. Has position.
0 · Reply
sDinvestments1
sDinvestments1 Jul. 31 at 7:34 PM
$NWBO $RGEN $CYRX $BLFS Some DD and info on the companies involved in the consumables, shipping, and cryo portions of cell therapies and NWBO’s own dcvax l processing. This started with the videos and pics that Braelyn’s mother shared of her recently traveling to the UK to get her first round of dcvax administered. I ran analysis on the shipper as i have actually seen this shipper before in two different airports. There is an advent link between CYRX and NWBO as well. I would very much like to own a pile of RGEN for a long long hold if we see a decent stockprice in the days following initial MHRA approval. @808right @Surforever @Thousandaire5 @IMA_FNG @TheWayISeeIt https://chatgpt.com/s/t_6a6cf55e50348191ba5f3ce43ecf5061
4 · Reply
Spicy_Trade
Spicy_Trade Jul. 28 at 11:51 PM
Repligen Corporation ( $RGEN ) SpicyTrade - Daily Stock Analysis https://youtu.be/1reNojBQD8A?si=HfR2SAW_0GgOzHan
0 · Reply
flychicken1991
flychicken1991 Jul. 28 at 7:15 PM
$RGEN Positive (70%): shares face upward price pressure because a stronger full-year outlook can prompt analysts to increase forward revenue and earnings estimates; the reported 13.8% gain indicates that repricing was already substantial. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/f9b45b434f05fbeb?utm_source=stocktwits&utm_medium=story_url
0 · Reply
notreload_ai
notreload_ai Jul. 28 at 4:15 PM
$RGEN posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09. https://notreload.xyz/xy/repligen-beats-q2-estimates-raises-2026-guidance/
0 · Reply
STACKD0E
STACKD0E Jul. 28 at 3:47 PM
$POLA $RGEN ✨
0 · Reply
EarningsInsider
EarningsInsider Jul. 28 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-28-repligen-co-stock/ $RGEN Repligen Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 28 at 11:18 AM
$RGEN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.09 down -65.38% YoY • Reported revenue of $204.13M up 11.93% YoY • Repligen Corporation raised its full year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted earnings per share guidance to $2.03-$2.09, based on expectations for the company's existing business.
0 · Reply
notreload_ai
notreload_ai Jul. 22 at 10:54 AM
$RGEN to acquire $BLFS in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026. https://notreload.xyz/xy/repligen-acquires-biolife-solutions-for-1-5b/
0 · Reply
UCIdidmyDD
UCIdidmyDD Jun. 27 at 6:40 PM
$RGEN this a Buffett, Lynch, anyone with a brain stock. i mean $LWAY dominates their market but its just not the comparison that you wanna do. nothing wrong with lifeway but its more proprietary to sybthesize protein A
0 · Reply
Latest News on RGEN
Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures

2026-07-29T13:52:33.000Z - 5 days ago

Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures

Repligen price target raised to $175 from $165 at JPMorgan

2026-07-29T12:03:01.000Z - 5 days ago

Repligen price target raised to $175 from $165 at JPMorgan

Repligen rises 15.4%

2026-07-28T16:05:46.000Z - 6 days ago

Repligen rises 15.4%

Repligen rises 16.2%

2026-07-28T14:05:42.000Z - 6 days ago

Repligen rises 16.2%

Repligen Earnings Call Transcript: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 6 days ago

Repligen Earnings Call Transcript: Q2 2026

Repligen Earnings release: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 6 days ago

Repligen Earnings release: Q2 2026

Repligen Slides: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 6 days ago

Repligen Slides: Q2 2026

Repligen Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 6 days ago

Repligen Quarterly report: Q2 2026

Repligen reports Q2 adjusted EPS 54c, consensus 45c

2026-07-28T11:12:08.000Z - 6 days ago

Repligen reports Q2 adjusted EPS 54c, consensus 45c

Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00

2026-07-28T11:10:41.000Z - 6 days ago

Repligen raises FY26 EPS view to $2.03-$2.09 from $1.97-$2.05, consensus $2.00

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Jul 28, 2026, 7:00 AM EDT - 6 days ago

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

Jul 23, 2026, 12:21 PM EDT - 11 days ago

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BLFS

BioLife Solutions downgraded to Hold from Buy at Lake Street

2026-07-22T14:40:21.000Z - 12 days ago

BioLife Solutions downgraded to Hold from Buy at Lake Street

BLFS

Repligen Transcript: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 12 days ago

Repligen Transcript: M&A announcement

Repligen Press release: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 12 days ago

Repligen Press release: M&A announcement

Repligen Slides: M&A announcement

Jul 22, 2026, 8:30 AM EDT - 12 days ago

Repligen Slides: M&A announcement

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

Jul 22, 2026, 6:13 AM EDT - 13 days ago

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

BLFS

Repligen to acquire BioLife Solutions for $31 per share, or $1.5B

2026-07-22T10:05:57.000Z - 13 days ago

Repligen to acquire BioLife Solutions for $31 per share, or $1.5B

BLFS

Repligen to acquire BioLife Solutions for $31 per share, or $1.5B

2026-07-22T10:05:11.000Z - 13 days ago

Repligen to acquire BioLife Solutions for $31 per share, or $1.5B

BLFS

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Jul 22, 2026, 6:00 AM EDT - 13 days ago

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

BLFS

Repligen to Report Second Quarter 2026 Financial Results

Jul 15, 2026, 7:30 AM EDT - 19 days ago

Repligen to Report Second Quarter 2026 Financial Results

Repligen upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:37.000Z - 4 weeks ago

Repligen upgraded to Buy from Hold at Benchmark

Repligen price target raised to $160 from $150 at Evercore ISI

2026-07-06T12:51:03.000Z - 4 weeks ago

Repligen price target raised to $160 from $150 at Evercore ISI

Biolife attracts takeover interest from Repligen, Bloomberg says

2026-06-26T22:15:10.000Z - 5 weeks ago

Biolife attracts takeover interest from Repligen, Bloomberg says

BLFS

Repligen Transcript: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 11:40 AM EDT - 2 months ago

Repligen Transcript: 46th Annual William Blair Growth Stock Conference

Repligen Slides: 46th Annual William Blair Growth Stock Conference

Jun 3, 2026, 11:40 AM EDT - 2 months ago

Repligen Slides: 46th Annual William Blair Growth Stock Conference

Repligen price target lowered to $150 from $170 at HSBC

2026-06-03T09:38:54.000Z - 2 months ago

Repligen price target lowered to $150 from $170 at HSBC

Repligen assumed with an Outperform at Wolfe Research

2026-06-01T20:43:43.000Z - 2 months ago

Repligen assumed with an Outperform at Wolfe Research

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

May 22, 2026, 7:30 AM EDT - 2 months ago

Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference

Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

May 20, 2026, 7:30 AM EDT - 2 months ago

Repligen Announces Publication of the Company's 2025 Corporate Sustainability Report

Repligen resumed with an Outperform at RBC Capital

2026-05-14T20:55:47.000Z - 2 months ago

Repligen resumed with an Outperform at RBC Capital

Repligen Transcript: AGM 2026

May 14, 2026, 8:00 AM EDT - 2 months ago

Repligen Transcript: AGM 2026

Repligen Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 1:00 PM EDT - 2 months ago

Repligen Transcript: Bank of America Global Healthcare Conference 2026

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

May 7, 2026, 7:30 AM EDT - 3 months ago

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

Repligen price target raised to $160 from $145 at Barclays

2026-05-07T10:15:25.000Z - 3 months ago

Repligen price target raised to $160 from $145 at Barclays

Repligen price target lowered to $165 from $180 at JPMorgan

2026-05-07T05:58:36.000Z - 3 months ago

Repligen price target lowered to $165 from $180 at JPMorgan

Repligen price target lowered to $142 from $152 at Jefferies

2026-05-05T19:45:16.000Z - 3 months ago

Repligen price target lowered to $142 from $152 at Jefferies

Repligen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Earnings Call Transcript: Q1 2026

Repligen Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Earnings release: Q1 2026

Repligen Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Slides: Q1 2026

Repligen Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Repligen Quarterly report: Q1 2026

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

May 5, 2026, 7:00 AM EDT - 3 months ago

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Repligen Proxy statement: Proxy filing

Repligen to Report First Quarter 2026 Financial Results

Apr 22, 2026, 7:30 AM EDT - 3 months ago

Repligen to Report First Quarter 2026 Financial Results

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Apr 17, 2026, 7:30 AM EDT - 3 months ago

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Repligen Proxy statement: Proxy filing

Repligen Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Repligen Proxy statement: Proxy filing

Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 18, 2026, 2:15 PM EDT - 4 months ago

Repligen Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Repligen Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 5 months ago

Repligen Transcript: Leerink Global Healthcare Conference 2026

Repligen Slides: Investor presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Repligen Slides: Investor presentation

Repligen Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Repligen Earnings Call Transcript: Q4 2025

Repligen Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Repligen Annual report: Q4 2025

Repligen Earnings release: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Repligen Earnings release: Q4 2025

Repligen Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 5 months ago

Repligen Annual report: Q4 2025

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 24, 2026, 7:30 AM EST - 5 months ago

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 10, 2026, 7:30 AM EST - 6 months ago

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

Repligen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Repligen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 7 months ago

Repligen Slides: 44th Annual J.P. Morgan Healthcare Conference

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Jan 6, 2026, 7:30 AM EST - 7 months ago

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Dec 18, 2025, 7:30 AM EST - 8 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Dec 16, 2025, 7:30 AM EST - 8 months ago

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 1:20 PM EST - 8 months ago

Repligen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 8 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

Repligen Transcript: Wolfe Research Healthcare Conference 2025

Nov 18, 2025, 12:40 PM EST - 9 months ago

Repligen Transcript: Wolfe Research Healthcare Conference 2025

Repligen Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:30 AM EST - 9 months ago

Repligen Transcript: Jefferies London Healthcare Conference 2025

Repligen Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 9 months ago

Repligen Transcript: Stifel 2025 Healthcare Conference

Repligen Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 11:00 AM EST - 9 months ago

Repligen Transcript: UBS Global Healthcare Conference 2025

Repligen Slides: Investor Presentation

Nov 9, 2025, 6:00 PM EST - 9 months ago

Repligen Slides: Investor Presentation

Repligen Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 9 months ago

Repligen Earnings Call Transcript: Q3 2025

Repligen Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 9 months ago

Repligen Quarterly report: Q3 2025

Repligen Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 9 months ago

Repligen Earnings release: Q3 2025

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 28, 2025, 7:30 AM EDT - 9 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Third Quarter 2025 Financial Results

Oct 15, 2025, 7:30 AM EDT - 10 months ago

Repligen to Report Third Quarter 2025 Financial Results

Repligen Transcript: Bank of America Global Healthcare Conference 2025

Sep 25, 2025, 6:35 AM EDT - 11 months ago

Repligen Transcript: Bank of America Global Healthcare Conference 2025

Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Repligen Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Repligen Corporation to Present at Upcoming September Conferences

Aug 22, 2025, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming September Conferences

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Repligen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q2 2025

Repligen Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Quarterly report: Q2 2025

Repligen Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings release: Q2 2025

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 29, 2025, 7:30 AM EDT - 1 year ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Repligen to Report Second Quarter 2025 Financial Results

Jul 17, 2025, 7:30 AM EDT - 1 year ago

Repligen to Report Second Quarter 2025 Financial Results

Repligen Slides: Investor Presentation

Jun 24, 2025, 9:00 AM EDT - 1 year ago

Repligen Slides: Investor Presentation

908 Devices Appoints Christopher D. Brown to its Board of Directors

Jun 16, 2025, 8:00 AM EDT - 1 year ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

Repligen Transcript: 45th Annual William Blair Growth Stock Conference

Jun 3, 2025, 2:20 PM EDT - 1 year ago

Repligen Transcript: 45th Annual William Blair Growth Stock Conference

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 27, 2025, 7:30 AM EDT - 1 year ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

Repligen Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Repligen Transcript: RBC Capital Markets Global Healthcare Conference 2025

Repligen Corporation to Present at Upcoming May Investor Conferences

May 7, 2025, 7:30 AM EDT - 1 year ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Repligen Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings Call Transcript: Q1 2025

Repligen Quarterly report: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Quarterly report: Q1 2025

Repligen Earnings release: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

Repligen Earnings release: Q1 2025

Repligen Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Repligen Reports First Quarter 2025 Financial Results

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing

Repligen Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing

Repligen Proxy statement: Proxy Filing

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Repligen Proxy statement: Proxy Filing

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Mar 4, 2025, 7:30 AM EST - 1 year ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Repligen Earnings Call Transcript: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q4 2024

Repligen Annual report: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Annual report: Q4 2024

Repligen Earnings release: Q4 2024

Feb 20, 2025, 8:30 AM EST - 1 year ago

Repligen Earnings release: Q4 2024

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 11, 2025, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Repligen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 4:30 PM EST - 1 year ago

Repligen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen Launches the CTech™ SoloVPE® PLUS System

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Repligen Transcript: Stephens 26th Annual Investment Conference | NASH2024

Nov 20, 2024, 11:00 AM EST - 1 year ago

Repligen Transcript: Stephens 26th Annual Investment Conference | NASH2024

Repligen Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 12:40 PM EST - 1 year ago

Repligen Transcript: Stifel 2024 Healthcare Conference

Repligen Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 10:15 AM EST - 1 year ago

Repligen Transcript: UBS Global Healthcare Conference 2024

Repligen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings Call Transcript: Q3 2024

Repligen Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Quarterly report: Q3 2024

Repligen Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Repligen Earnings release: Q3 2024

Repligen Corporation to Present at Upcoming Investor Conferences

Nov 5, 2024, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at Upcoming Investor Conferences

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Oct 14, 2024, 11:15 AM EDT - 1 year ago

Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Sep 24, 2024, 7:30 AM EDT - 2 years ago

Repligen Opens Training & Innovation Center to Elevate Customer Experience

Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Sep 6, 2024, 8:45 AM EDT - 2 years ago

Repligen Transcript: 2024 Wells Fargo Healthcare Conference

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Aug 23, 2024, 7:30 AM EDT - 2 years ago

Repligen Corporation to Present at Wells Fargo Healthcare Conference

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

Aug 16, 2024, 11:46 AM EDT - 2 years ago

Exclusive: Repligen in bid for reagent vendor Maravai, sources say

MRVI

Repligen Earnings Call Transcript: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q2 2024

Repligen Quarterly report: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Quarterly report: Q2 2024

Repligen Earnings release: Q2 2024

Jul 30, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings release: Q2 2024

Repligen Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports Second Quarter 2024 Financial Results

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Jul 29, 2024, 4:00 PM EDT - 2 years ago

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Repligen to Report Second Quarter 2024 Financial Results

Jul 16, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report Second Quarter 2024 Financial Results

Repligen Announces CEO Transition Plan

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Repligen Announces CEO Transition Plan

Repligen Transcript: Jefferies Global Healthcare Conference

Jun 6, 2024, 11:30 AM EDT - 2 years ago

Repligen Transcript: Jefferies Global Healthcare Conference

Repligen Transcript: The 44th Annual William Blair Growth Stock Conference

Jun 5, 2024, 1:00 PM EDT - 2 years ago

Repligen Transcript: The 44th Annual William Blair Growth Stock Conference

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing

Repligen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

May 30, 2024, 9:40 AM EDT - 2 years ago

Repligen Transcript: 2024 Leerink Partners Healthcare Crossroads Conference

Repligen Corporation to Present at Upcoming June Investor Conferences

May 22, 2024, 7:30 AM EDT - 2 years ago

Repligen Corporation to Present at Upcoming June Investor Conferences

Repligen Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 14, 2024, 10:30 AM EDT - 2 years ago

Repligen Transcript: 2024 RBC Capital Markets Global Healthcare Conference

Repligen Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing

Repligen Earnings Call Transcript: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings Call Transcript: Q1 2024

Repligen Quarterly report: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Quarterly report: Q1 2024

Repligen Earnings release: Q1 2024

May 1, 2024, 8:30 AM EDT - 2 years ago

Repligen Earnings release: Q1 2024

Repligen Reports First Quarter 2024 Financial Results

May 1, 2024, 7:30 AM EDT - 2 years ago

Repligen Reports First Quarter 2024 Financial Results

Repligen to Report First Quarter 2024 Financial Results

Apr 17, 2024, 7:30 AM EDT - 2 years ago

Repligen to Report First Quarter 2024 Financial Results

Repligen Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing

Repligen Proxy statement: Proxy Filing

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Repligen Proxy statement: Proxy Filing

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 20, 2024, 3:00 PM EDT - 2 years ago

Repligen Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Repligen Appoints Maggie A. Pax to Board of Directors

Mar 19, 2024, 7:30 AM EDT - 2 years ago

Repligen Appoints Maggie A. Pax to Board of Directors

vjtweet
vjtweet Aug. 4 at 2:22 AM
$RGEN Noisy but 200 should be possible in few months. Has position.
0 · Reply
sDinvestments1
sDinvestments1 Jul. 31 at 7:34 PM
$NWBO $RGEN $CYRX $BLFS Some DD and info on the companies involved in the consumables, shipping, and cryo portions of cell therapies and NWBO’s own dcvax l processing. This started with the videos and pics that Braelyn’s mother shared of her recently traveling to the UK to get her first round of dcvax administered. I ran analysis on the shipper as i have actually seen this shipper before in two different airports. There is an advent link between CYRX and NWBO as well. I would very much like to own a pile of RGEN for a long long hold if we see a decent stockprice in the days following initial MHRA approval. @808right @Surforever @Thousandaire5 @IMA_FNG @TheWayISeeIt https://chatgpt.com/s/t_6a6cf55e50348191ba5f3ce43ecf5061
4 · Reply
Spicy_Trade
Spicy_Trade Jul. 28 at 11:51 PM
Repligen Corporation ( $RGEN ) SpicyTrade - Daily Stock Analysis https://youtu.be/1reNojBQD8A?si=HfR2SAW_0GgOzHan
0 · Reply
flychicken1991
flychicken1991 Jul. 28 at 7:15 PM
$RGEN Positive (70%): shares face upward price pressure because a stronger full-year outlook can prompt analysts to increase forward revenue and earnings estimates; the reported 13.8% gain indicates that repricing was already substantial. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/f9b45b434f05fbeb?utm_source=stocktwits&utm_medium=story_url
0 · Reply
notreload_ai
notreload_ai Jul. 28 at 4:15 PM
$RGEN posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09. https://notreload.xyz/xy/repligen-beats-q2-estimates-raises-2026-guidance/
0 · Reply
STACKD0E
STACKD0E Jul. 28 at 3:47 PM
$POLA $RGEN ✨
0 · Reply
EarningsInsider
EarningsInsider Jul. 28 at 1:16 PM
https://www.marketbeat.com/earnings/reports/2026-7-28-repligen-co-stock/ $RGEN Repligen Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jul. 28 at 11:18 AM
$RGEN Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.09 down -65.38% YoY • Reported revenue of $204.13M up 11.93% YoY • Repligen Corporation raised its full year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted earnings per share guidance to $2.03-$2.09, based on expectations for the company's existing business.
0 · Reply
notreload_ai
notreload_ai Jul. 22 at 10:54 AM
$RGEN to acquire $BLFS in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026. https://notreload.xyz/xy/repligen-acquires-biolife-solutions-for-1-5b/
0 · Reply
UCIdidmyDD
UCIdidmyDD Jun. 27 at 6:40 PM
$RGEN this a Buffett, Lynch, anyone with a brain stock. i mean $LWAY dominates their market but its just not the comparison that you wanna do. nothing wrong with lifeway but its more proprietary to sybthesize protein A
0 · Reply
UCIdidmyDD
UCIdidmyDD Jun. 26 at 9:27 PM
$RGEN yeah so i owned this in the 3-4$ range in the 00’s. Herlihy ? was tbe CEO. thats when the run began. anywho, a bit older but back in today for a starter.
0 · Reply
vjtweet
vjtweet Jun. 4 at 3:28 PM
$RGEN Opened new long position.
1 · Reply
SuperGreenToday
SuperGreenToday May. 21 at 5:15 PM
$RGEN Share Price: $112.18 Contract Selected: Nov 20, 2026 $115 Calls Buy Zone: $12.92 – $15.96 Target Zone: $21.68 – $26.50 Potential Upside: 58% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Estimize
Estimize May. 21 at 11:00 AM
Wall St is expecting 0.45 EPS for $RGEN Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply
scdtrader213
scdtrader213 May. 19 at 12:23 AM
$MRK fantastic news, not good for. $RGEN “Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial
0 · Reply
BullsOnPrade
BullsOnPrade May. 18 at 1:08 PM
$VKTX BO $REGN? Or $RGEN BO $IOVA?
1 · Reply
Optionshmoptions
Optionshmoptions May. 15 at 6:56 PM
$RGEN brutal
0 · Reply
jewell69
jewell69 May. 15 at 3:08 PM
$RGEN lost on this one, but it is one of very few that are up today. source of funds for something else. today seems like a bunch of buy, on market at close type of day. 05/15/2026 Sell Edit cost basis method RGEN REPLIGEN CORP 37 $105.64 $0.09 $3,908.59 More 05/13/2026 Buy RGEN REPLIGEN CORP 8 $107.90 -$863.20 More 05/12/2026 Buy RGEN REPLIGEN CORP 29 $115.45 -$3,348.05
0 · Reply
jewell69
jewell69 May. 12 at 7:36 PM
$RGEN re-entry; SO EASY, EVEN A CAVEMAN CAN DO IT 05/12/2026 Buy RGEN REPLIGEN CORP 29 $115.45 -$3,348.05 More 05/04/2026 Sell RGEN REPLIGEN CORP 28 $118.98 $0.08 $3,331.36 More 04/29/2026 Buy RGEN REPLIGEN CORP 28 $112.80 -$3,158.40 More 04/28/2026 Sell RGEN REPLIGEN CORP 28 $117.73 $0.08 $3,296.36 More 04/28/2026 Buy RGEN REPLIGEN CORP 28 $116.98 -$3,275.44 More 04/27/2026 Sell RGEN REPLIGEN CORP 28 $118.07 $0.08 $3,305.88 More 04/24/2026 Buy RGEN REPLIGEN CORP 28 $115.75 -$3,241.00
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 12:21 PM
$RGEN Current Stock Price: $123.35 Contracts to trade: $125.0 RGEN May 15 2026 Call Entry: $2.72 Exit: $4.43 ROI: 63% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
vjtweet
vjtweet May. 8 at 4:09 PM
$RGEN has buy order at 128. That is the prior breakout point and the current action says buyers holding strong.
0 · Reply
Estimize
Estimize May. 6 at 10:00 AM
Wall St is expecting 0.46 EPS for $RGEN Q2 [Reporting 08/04 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co
0 · Reply